The publication of the Impact Assessment and Legislative Proposal on the revised blood, tissues and cells (BTC) legislation is now confirmed to be published in Q1 2022.

In BTA's view, the classification guidance document still leaves room for interpretation as to how blood bag sets containing citrate-based anticoagulant solutions should be classified.

The publication of the amendment to Annex XIV of REACH sets in stone the proposed sunset date for removing products containing DEHP from the EU market.  

On 4 October, the Medical Device Coordination Group (MDCG) published the long-awaited guidance document on classification of medical devices under the new Medical Device Regulation (MDR).

The long-awaited MDCG classification guidance document under the new MDR is still to be published by the European Commission.

On 23 July, the BTA submitted a response to the targeted stakeholder consultation on the revision of the EU legislation on blood, tissues and cells (BTC).

The BTA submits a response to a public consultation on the Inception Impact Assessment (IIA) of the REACH regulation.

Originally published in 2016, the REACH Regulation regulates the use of chemicals across the EU in all industries in order to improve human health and the environment.

In October 2020, the Commission set in stone its priority to revise of the EU legislation on blood, tissues and cells.

The BTA is proud to announce that Hemanext will also be joining the association’s membership.

The BTA warmly welcomes Grifols, a new addition to the list of members forming part of the Association.

The United Kingdom (UK) and the European Union (EU)’s chemical industries are currently heavily intertwined. Given the UK’s exit of the EU, measures are needed to ensure that the UK has a chemical…

As a new association, 2020 has been an interesting year for the BTA. From creating our visual identity, to establishing a wide network in the blood transfusion area, we explore some of our key…

On 10 November the European Commission welcomed the agreement between the European Parliament and EU Member States in the Council on Europe's next long-term budget for 2021-2027, including EU4Health.…

The need to increase supply of blood products such as plasma has been brought to the forefront in view of the COVID-19 pandemic, both as a potential therapy to the Sars-CoV-2 virus and to enable…

The Council of Europe - European Directorate for the Quality of Medicines (EDQM) held a three-day webinar entitled “Keeping up with Reality and Quality: A Challenge for European Blood Establishments”…

The NHS Blood and Transplant is (NHSBT) announced on 19 October the opening of 14 more blood plasma donation centres. The opening of these centres will improve access by potential donors. The NHS…

The BTA has successfully joined the European Directorate for the Quality of Medicines (EDQM) group working on a Blood Supply Contingency and Emergency Plan (B-SCEP). The overall objective of the…

A Pan-European Commission on Health and Sustainable Development was convened in August by the World Health Organisation (WHO)’s Regional Office for Europe. This Commission will revisit policy…

The BTA was approached by the European Commission to provide information regarding the member’s activities within the field of plasma collection. On 31 July the European Commission announced the…

The World Health Organisation (WHO) published an interim guidance on maintaining a safe and adequate blood supply during the COVID-19 crisis. The document provides recommendations on donor deferral,…

The Environment, Public Health and Food Safety Committee (ENVI) of the European Parliament adopted a resolution calling on the European Commission to minimise the exposure to hazardous chemicals…